These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 9632373)

  • 1. Nonsymmetric P2/P2' cyclic urea HIV protease inhibitors. Structure-activity relationship, bioavailability, and resistance profile of monoindazole-substituted P2 analogues.
    De Lucca GV; Kim UT; Liang J; Cordova B; Klabe RM; Garber S; Bacheler LT; Lam GN; Wright MR; Logue KA; Erickson-Viitanen S; Ko SS; Trainor GL
    J Med Chem; 1998 Jun; 41(13):2411-23. PubMed ID: 9632373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclic HIV protease inhibitors: design and synthesis of orally bioavailable, pyrazole P2/P2' cyclic ureas with improved potency.
    Han Q; Chang CH; Li R; Ru Y; Jadhav PK; Lam PY
    J Med Chem; 1998 Jun; 41(12):2019-28. PubMed ID: 9622543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereospecific synthesis, structure-activity relationship, and oral bioavailability of tetrahydropyrimidin-2-one HIV protease inhibitors.
    De Lucca GV; Liang J; De Lucca I
    J Med Chem; 1999 Jan; 42(1):135-52. PubMed ID: 9888839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent cyclic urea HIV protease inhibitors with 3-aminoindazole P2/P2' groups.
    Rodgers JD; Johnson BL; Wang H; Erickson-Viitanen S; Klabe RM; Bacheler L; Cordova BC; Chang CH
    Bioorg Med Chem Lett; 1998 Apr; 8(7):715-20. PubMed ID: 9871528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors.
    Rodgers JD; Lam PY; Johnson BL; Wang H; Li R; Ru Y; Ko SS; Seitz SP; Trainor GL; Anderson PS; Klabe RM; Bacheler LT; Cordova B; Garber S; Reid C; Wright MR; Chang CH; Erickson-Viitanen S
    Chem Biol; 1998 Oct; 5(10):597-608. PubMed ID: 9818151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Possible allosteric interactions of monoindazole-substituted P2 cyclic urea analogues with wild-type and mutant HIV-1 protease.
    Garg R; Bhhatarai B
    J Comput Aided Mol Des; 2008 Oct; 22(10):737-45. PubMed ID: 18368496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450.
    Hodge CN; Aldrich PE; Bacheler LT; Chang CH; Eyermann CJ; Garber S; Grubb M; Jackson DA; Jadhav PK; Korant B; Lam PY; Maurin MB; Meek JL; Otto MJ; Rayner MM; Reid C; Sharpe TR; Shum L; Winslow DL; Erickson-Viitanen S
    Chem Biol; 1996 Apr; 3(4):301-14. PubMed ID: 8807858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance to HIV protease inhibitors: a comparison of enzyme inhibition and antiviral potency.
    Klabe RM; Bacheler LT; Ala PJ; Erickson-Viitanen S; Meek JL
    Biochemistry; 1998 Jun; 37(24):8735-42. PubMed ID: 9628735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV.
    Jadhav PK; Ala P; Woerner FJ; Chang CH; Garber SS; Anton ED; Bacheler LT
    J Med Chem; 1997 Jan; 40(2):181-91. PubMed ID: 9003516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular basis of HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with cyclic urea inhibitors.
    Ala PJ; Huston EE; Klabe RM; McCabe DD; Duke JL; Rizzo CJ; Korant BD; DeLoskey RJ; Lam PY; Hodge CN; Chang CH
    Biochemistry; 1997 Feb; 36(7):1573-80. PubMed ID: 9048541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 Protease Inhibitors Incorporating Stereochemically Defined P2' Ligands To Optimize Hydrogen Bonding in the Substrate Envelope.
    Rusere LN; Lockbaum GJ; Lee SK; Henes M; Kosovrasti K; Spielvogel E; Nalivaika EA; Swanstrom R; Yilmaz NK; Schiffer CA; Ali A
    J Med Chem; 2019 Sep; 62(17):8062-8079. PubMed ID: 31386368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclic HIV protease inhibitors: synthesis, conformational analysis, P2/P2' structure-activity relationship, and molecular recognition of cyclic ureas.
    Lam PY; Ru Y; Jadhav PK; Aldrich PE; DeLucca GV; Eyermann CJ; Chang CH; Emmett G; Holler ER; Daneker WF; Li L; Confalone PN; McHugh RJ; Han Q; Li R; Markwalder JA; Seitz SP; Sharpe TR; Bacheler LT; Rayner MM; Klabe RM; Shum L; Winslow DL; Kornhauser DM; Hodge CN
    J Med Chem; 1996 Aug; 39(18):3514-25. PubMed ID: 8784449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved P1/P1' substituents for cyclic urea based HIV-1 protease inhibitors: synthesis, structure-activity relationship, and X-ray crystal structure analysis.
    Nugiel DA; Jacobs K; Cornelius L; Chang CH; Jadhav PK; Holler ER; Klabe RM; Bacheler LT; Cordova B; Garber S; Reid C; Logue KA; Gorey-Feret LJ; Lam GN; Erickson-Viitanen S; Seitz SP
    J Med Chem; 1997 May; 40(10):1465-74. PubMed ID: 9154969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unsymmetrical cyclic ureas as HIV-1 protease inhibitors: novel biaryl indazoles as P2/P2' substituents.
    Patel M; Rodgers JD; McHugh RJ; Johnson BL; Cordova BC; Klabe RM; Bacheler LT; Erickson-Viitanen S; Ko SS
    Bioorg Med Chem Lett; 1999 Nov; 9(22):3217-20. PubMed ID: 10576691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-based design, synthesis, and structure-activity relationship studies of HIV-1 protease inhibitors incorporating phenyloxazolidinones.
    Ali A; Reddy GS; Nalam MN; Anjum SG; Cao H; Schiffer CA; Rana TM
    J Med Chem; 2010 Nov; 53(21):7699-708. PubMed ID: 20958050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonpeptide cyclic cyanoguanidines as HIV-1 protease inhibitors: synthesis, structure-activity relationships, and X-ray crystal structure studies.
    Jadhav PK; Woerner FJ; Lam PY; Hodge CN; Eyermann CJ; Man HW; Daneker WF; Bacheler LT; Rayner MM; Meek JL; Erickson-Viitanen S; Jackson DA; Calabrese JC; Schadt M; Chang CH
    J Med Chem; 1998 Apr; 41(9):1446-55. PubMed ID: 9554878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonsymmetrically substituted cyclic urea HIV protease inhibitors.
    Wilkerson WW; Dax S; Cheatham WW
    J Med Chem; 1997 Dec; 40(25):4079-88. PubMed ID: 9406598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent inhibitors of the HIV-1 protease incorporating cyclic urea P1-P2 scaffold.
    Kazmierski WM; Furfine E; Gray-Nunez Y; Spaltenstein A; Wright L
    Bioorg Med Chem Lett; 2004 Nov; 14(22):5685-7. PubMed ID: 15482948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV protease inhibitory bis-benzamide cyclic ureas: a quantitative structure-activity relationship analysis.
    Wilkerson WW; Akamike E; Cheatham WW; Hollis AY; Collins RD; DeLucca I; Lam PY; Ru Y
    J Med Chem; 1996 Oct; 39(21):4299-312. PubMed ID: 8863807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis, antiviral activity and pharmacokinetics of P1/P1' substituted 3-aminoindazole cyclic urea HIV protease inhibitors.
    Kaltenbach RF; Patel M; Waltermire RE; Harris GD; Stone BR; Klabe RM; Garber S; Bacheler LT; Cordova BC; Logue K; Wright MR; Erickson-Viitanen S; Trainor GL
    Bioorg Med Chem Lett; 2003 Feb; 13(4):605-8. PubMed ID: 12639540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.